Max IndiaNSE:MAXIND -3.94%66 EBITDA Margin % is -13.41% as of Mar. 2026. GuruFocus rates NSE:MAXIND with a GF Score™ of 66/100 and a GF Value™ of ₹205.35 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 668 Healthcare Providers & Services companies, Max India ranks worse than 86.83% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Max India's EBITDA for the
three
months ended in Mar. 2026 was ₹-88 Mil. Max India's Revenue for the
three
months ended in Mar. 2026 was ₹656 Mil. Therefore, Max India's EBITDA margin for the quarter that ended in Mar. 2026 was -13.41%.
Max India (NSE:MAXIND) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Max India EBITDA Margin % Related Terms
Max India EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Max India's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:MAXIND vs HCA, THC, DVA: EBITDA Margin % Comparison
For the Medical Care Facilities subindustry, Max India's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Max India EBITDA Margin % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Max India's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Max India's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Max India (NSE:MAXIND) has a EBITDA Margin % of -13.41% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Max India and its competitors. According to the industry distribution chart, Max India ranks #580 out of 668 companies in the Healthcare Providers & Services industry, placing it in the top 86.8%.
Is Max India's EBITDA Margin % too high?
Max India's current EBITDA Margin % is -13.41%. Based on the distribution chart, Max India ranks #580 out of 668 companies in the Healthcare Providers & Services industry, which is in the bottom quartile relative to peers. Overall, Max India has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Max India's EBITDA Margin % compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Max India ranks #580 out of 668 companies for EBITDA Margin %. This places Max India in the lower half of its industry. The industry median EBITDA Margin % is 10.21. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Healthcare Providers & Services company?
The median EBITDA Margin % among Healthcare Providers & Services companies is 10.21, based on 668 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Max India and its competitors. For the Healthcare Providers & Services industry, the median EBITDA Margin % is 10.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Max India's current EBITDA Margin % is -13.41%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Max India stock overvalued right now?
Based on GuruFocus' analysis, Max India (NSE:MAXIND) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹205.35, compared to a current price of ₹159.04 — trading 22.6% below its estimated fair value. The current EBITDA Margin % is -13.41%. Max India's overall GF Score™ is 66/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Max India (NSE:MAXIND), the current EBITDA Margin % is -13.41% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Max India (NSE:MAXIND) Overvalued in 2026?
Based on GuruFocus' analysis, Max India stock appears to be undervalued.
The current stock price of ₹159.04 is trading 22.6% below its estimated GF Value™ of ₹205.35.
GuruFocus considers Max India to be Modestly Undervalued.
Key valuation signals for NSE:MAXIND:
EBITDA Margin %: -13.41%
GF Value™: ₹205.35 vs. price of ₹159.04 (22.6% below fair value)
No single metric tells the full story. See the NSE:MAXIND stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Max India Ltd is a multi-business corporate that operates in the healthcare sector. The company provides healthcare services. Also, the company provides health insurance policies, senior-living communities, and other health-related training services. The business operates in four segments namely, Business Investments, Senior Living, Assisted Care, and Other. It derives maximum revenue from Senior Living segment.
66GF Score
Get the complete analysis for NSE:MAXIND
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MAXIND has been successfully added to your 
